vTv Therapeutics (NASDAQ:VTVT) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report released on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners began coverage on vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 target price on the stock.

vTv Therapeutics Stock Down 3.3 %

VTVT stock opened at $20.20 on Friday. The business has a 50 day moving average price of $15.68 and a 200 day moving average price of $15.11. The stock has a market cap of $64.44 million, a price-to-earnings ratio of -4.46 and a beta of 0.73. vTv Therapeutics has a fifty-two week low of $8.10 and a fifty-two week high of $30.99.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC acquired a new stake in vTv Therapeutics in the third quarter valued at $2,402,000. JPMorgan Chase & Co. acquired a new stake in vTv Therapeutics in the 4th quarter valued at about $25,000. Finally, Geode Capital Management LLC grew its stake in vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares during the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.